Blood Glucose Determinations Differ in Plasma and Serum
|
By LabMedica International staff writers Posted on 05 Jul 2012 |
Blood glucose determination is one of the most common clinical diagnostic tests and accurate and precise measurement of blood glucose is of great importance in the diagnosis and management of diabetes.
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
The concentration of glucose in the blood will continue to decrease over time after phlebotomy because of glycolysis, which will occur in erythrocytes, white blood cells (WBCs), and platelets as these cells can continue to metabolize glucose.
Laboratory scientists at the University of Mysore, (Manasagangotri, India) investigated the effect of time and the method of processing of blood on the blood glucose levels. Blood from 30 different patients who came for routine blood glucose determination were used in the study. Whole blood was divided into three portions. One portion was allowed to clot. To the second portion, 2mg/mL sodium fluoride was added, and to the third portion, ethylene diamine tetra acetic acid (EDTA)–disodium salt was added.
Blood sugar was estimated using a blood sugar assay kit (Becton Dickinson, Bangalore, India). Optical Density (OD) of the colored complex was measured at 620 nm in an autoanalyzer. Blood sugar in these samples stored at room temperature was measured again after four hours and eight hours. The serum gave values lower than fluoride plasma by 1.15%. Although this difference was statistically significant, it may not be physiologically relevant. On storing the sample at room temperature for eight hours, the serum glucose value decreased by 8% and even fluoride plasma had 4.3% lower glucose.
The authors concluded that blood glucose should be determined within as short a time as possible after drawing the blood. The blood glucose values ranged from 76 to 410 mg/dL covering a wide range of blood glucose values that would be seen in any sample analysis. Serum may be a better sample for blood glucose determination particularly when there is a time delay in the measurement. If appropriate correction is applied, it may actually be a better sample than plasma. Moreover, many clinical analysis procedures require serum rather than plasma and therefore one single drawing of blood may suffice for even blood glucose estimation. The study was published online on May 14, 2012, in the Journal of Clinical Laboratory Analysis.
Related Links:
University of Mysore
Becton Dickinson
Latest Clinical Chem. News
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
- Automated NfL Assay Supports Monitoring of Neurological Disorders
- Blood-Based Screening Test Targets Early Detection of Colorectal Cancer
- New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
- CSF Biomarker Improves Diagnosis of Parkinson’s Disease and Lewy Body Dementia
- Simple Urine Home Test Kit Could Detect Early-Stage Breast Cancer
- Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
- New Tool Tracks Biomarker Changes to Predict Myeloma Progression
- New Plasma Tau Assay Improves Prediction of Alzheimer’s Progression
- First IVD Immunoassay to Detect Alzheimer’s Risk Gene Variant Receives CE Mark
Channels
Molecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read more
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read moreMicrobiology
view channel
Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
Melanoma remains prone to relapse even after surgery and adjuvant immunotherapy, with 25% to 40% of patients experiencing recurrence. Clinicians lack reliable pre-treatment indicators to identify those... Read more
Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
Gram-negative bloodstream infections and sepsis demand fast, precise antimicrobial therapy, yet conventional susceptibility workflows can delay targeted treatment. Clinical laboratories need platforms... Read morePathology
view channel
AI Pathology Model Predicts Immunotherapy Response in Lung Cancer
Clinicians face persistent challenges identifying which patients with metastatic non-small cell lung cancer will benefit from immunotherapy, even as these agents transform oncology care.... Read more
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more




.jpg)


